Bhellum Pyrus, Goyal Rajat, Khichar Satyendra, Vishwajeet Vikarn, Yalla Harshita
Department of General Medicine, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND.
Department of Pathology and Lab Medicine, All India Institute of Medical Sciences, Jodhpur, Jodhpur, IND.
Cureus. 2025 Jul 11;17(7):e87736. doi: 10.7759/cureus.87736. eCollection 2025 Jul.
Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of diffuse large B-cell lymphoma (DLBCL), often associated with immunodeficiency states such as HIV infection. However, PBL can also occur in HIV-negative individuals, where it exhibits diverse anatomical involvement and poorer prognosis. This case presents a 50-year-old HIV negative male patient with progressive lower limb weakness and numbness due to a thoracic paravertebral lesion extending from T1 to T6, causing compressive myelopathy. Imaging raised concerns for malignancy, and histopathology confirmed PBL with positivity on IHC for CD38, CD138, and Cyclin D1. Given its aggressive nature, early intervention was critical. The patient underwent surgical decompression via T2-T6 laminectomy followed by chemotherapy with the EPOCH regimen (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). After two cycles, significant symptomatic improvement was observed. HIV-negative PBL is associated with poor prognosis and high relapse rates, necessitating aggressive treatment and close monitoring. This case highlights the challenges in diagnosing and managing HIV-negative PBL, emphasizing the importance of multimodal treatment strategies, including surgical intervention, intensive chemotherapy, and follow-up.
浆母细胞性淋巴瘤(PBL)是弥漫性大B细胞淋巴瘤(DLBCL)的一种罕见且侵袭性亚型,常与免疫缺陷状态如HIV感染相关。然而,PBL也可发生于HIV阴性个体,在此情况下它表现出不同的解剖部位受累且预后较差。本病例介绍了一名50岁HIV阴性男性患者,因从T1至T6的胸椎旁病变导致进行性下肢无力和麻木,引起压迫性脊髓病。影像学检查引发了对恶性肿瘤的担忧,组织病理学确诊为PBL,免疫组化显示CD38、CD138和细胞周期蛋白D1呈阳性。鉴于其侵袭性,早期干预至关重要。患者接受了经T2 - T6椎板切除术的手术减压,随后采用EPOCH方案(依托泊苷、泼尼松、长春新碱、环磷酰胺、阿霉素)进行化疗。两个周期后,观察到症状有显著改善。HIV阴性PBL与预后不良和高复发率相关,需要积极治疗和密切监测。本病例突出了诊断和管理HIV阴性PBL的挑战,强调了多模式治疗策略的重要性,包括手术干预、强化化疗和随访。